Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Master Prize: Award for the Best Graduate in Pharmaceutical Sciences at the University of Munich

Claudia Hildebrandt received the Daiichi Sankyo Master Prize 2014: Award for the best graduate of Pharmaceutical Sciences at the Ludwig-Maximilians-University Munich (LMU)

Munich, 1 December 2014 – It is a special award for talents in the Pharmaceutical Sciences: For the last six years Daiichi Sankyo Europe has presented outstanding graduates of Pharmaceutical Sciences at the University of Munich with the „Daiichi Sankyo Master Prize”.

Award Winner from Pfaffenhofen, Bavaria

This year’s award winner Claudia Hildebrandt was born and raised in Pfaffenhofen which happens to be the hometown of Daiichi Sankyo’s manufacturing site, the largest production and development site outside of Japan. Some years ago Hildebrandt had already been the best Bachelor Student. In 2014 she is the best graduate of the Master Studies in Pharmaceutical Sciences. She wrote her thesis about drug target identification and plans to continue examining how compounds can be turned into successful drugs.

“We created the award to support new and promising scientific talents in Pharmaceutical Sciences”, says Priv. Doz. Dr. Nora Urbanetz. She is responsible for Pharmaceutical Development at Daiichi Sankyo and was the one to hand over the award to Hildebrandt during the graduation ceremony at the Ludwig-Maximilians-University Munich (LMU).

Investing in Research and Development

Research and Development (R&D) are very important for Daiichi Sankyo. The pharmaceutical company invests more than 17 percent of its net sales into R&D. Among its 2.200 employees in Europe there are about two hundred qualified experts working especially for R&D projects.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com

About Daiichi Sankyo Europe

Daiichi Sankyo’s European base is located in Munich and has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit: www.daiichi-sankyo.eu

Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of Daiichi Sankyo Europe GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, inclu¬ding the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. Daiichi Sankyo Europe GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.